Victrex’s (VCT) Buy Rating Reaffirmed at Liberum Capital

Victrex (LON:VCT)‘s stock had its “buy” rating reaffirmed by Liberum Capital in a report released on Monday. They presently have a GBX 2,770 ($38.90) price target on the stock. Liberum Capital’s target price points to a potential upside of 13.06% from the stock’s current price.

Several other analysts also recently issued reports on the company. JPMorgan Chase & Co. raised their price target on Victrex from GBX 2,250 ($31.60) to GBX 2,580 ($36.23) and gave the stock a “neutral” rating in a report on Monday, January 8th. Barclays cut their price target on Victrex from GBX 2,350 ($33.00) to GBX 2,270 ($31.88) and set an “equal weight” rating on the stock in a report on Tuesday, November 28th. Berenberg Bank reissued a “buy” rating and issued a GBX 2,600 ($36.51) price target on shares of Victrex in a report on Tuesday, December 5th. Peel Hunt downgraded Victrex to a “hold” rating and set a GBX 2,300 ($32.30) price target on the stock. in a report on Tuesday, October 31st. Finally, Deutsche Bank reissued a “hold” rating and issued a GBX 2,200 ($30.89) price target on shares of Victrex in a report on Thursday, January 4th. Eight analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of GBX 2,309.80 ($32.44).

Victrex (VCT) opened at GBX 2,450 ($34.41) on Monday. The company has a market capitalization of $2,100.00 and a P/E ratio of 2,112.07. Victrex has a 12-month low of GBX 1,826 ($25.64) and a 12-month high of GBX 2,772 ($38.93).

In other Victrex news, insider Martin Court sold 441 shares of Victrex stock in a transaction on Friday, December 15th. The stock was sold at an average price of GBX 2,618 ($36.76), for a total transaction of £11,545.38 ($16,213.14). Insiders have acquired a total of 14 shares of company stock worth $36,018 in the last ninety days.

COPYRIGHT VIOLATION NOTICE: “Victrex’s (VCT) Buy Rating Reaffirmed at Liberum Capital” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/02/05/victrexs-vct-buy-rating-reaffirmed-at-liberum-capital.html.

About Victrex

Victrex plc is a United Kingdom-based holding company. The Company is engaged in the manufacture and sale of various polymers. The Company’s operating segments include Industrial (Victrex Polymer Solutions) and Medical (Invibio Biomaterial Solutions). The Victrex Polymer Solutions segment focuses on automotive, aerospace, electronics and energy markets.

Analyst Recommendations for Victrex (LON:VCT)

Receive News & Ratings for Victrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Victrex and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply